Central nervous system–restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation by Hojun Li, Leslie A. Benson,

Slides:



Advertisements
Similar presentations
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
Advertisements

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Volume 20, Issue 2, (February 2012)
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.
Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact.
How I treat extramedullary myeloma
by Eli L. Diamond, Lorenzo Dagna, David M
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
by Rahul Matnani, and Karthik A. Ganapathi
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells by Lucie Heinzerling,
Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation by George E. Georges, Rainer Storb, Jennifer.
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance by Elisabetta Antonioli, Paola Guglielmelli,
Figure Neuroimaging and pathology
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.
Genetics of HLH (Hemophagocytic Lymphohistiocytosis)
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Figure Radiographic and histopathologic findings (A) Brain MRI at presentation shows multiple areas of T2 hyperintensity in the mesial temporal lobes,
Evidence of a Graft-versus-Hodgkin Lymphoma Effect in the Setting of Extensive Bone Marrow Involvement  Paolo Anderlini, MD  Biology of Blood and Marrow.
Keith M. Sullivan, Paolo Muraro, Alan Tyndall 
Figure 3 Ultra-high-field MRI at 7.0T (patients 5 and 6)‏
by Alex Aleshin, and Peter L. Greenberg
Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis
Overall survival by SCT versus observation in first complete remission
by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.
by Geling Li, Emily Waite, and Julie Wolfson
by Kaiwen Chen, Matthew P. Cheng, Sarah P
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Volume 2(Supplement 1):46-49
Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH by Alexandra Kolenová, Raphaela Schwentner,
Serial imaging of a child with a clinical complex of bilateral facial PWS, early-onset severe seizures, and fatally progressive encephalopathy. Serial.
Figure 2 Evolution of blood cell counts during interleukin (IL)–7 therapy Evolution of blood cell counts during interleukin (IL)–7 therapy The leukocyte.
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings.
LITERATURE REVIEW.
Bridge to transplant following Bv+Bs regimen.
Skeletal abnormalities and successful hematopoietic stem cell transplantation in patients with reticular dysgenesis  Daifulah Al-Zahrani, MD, Abdulaziz.
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.
Figure 1 MRIs (case 1)‏ MRIs (case 1) An enlarging T2 lesion in the cerebral white matter near the angular gyrus and a new lesion in the left middle cerebellar.
Figure 1 Imaging and histopathologic characteristics of patients with CNS-FHL Imaging and histopathologic characteristics of patients with CNS-FHL FLAIR.
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.
Overview of the treatment protocol HLH-94
Resistance mechanism for ibrutinib in marginal zone lymphoma
How I treat hemophagocytic lymphohistiocytosis
Figure 4 Patient 3 MRI evolution over time
Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity by Benjamin L. Lampson, Siddha.
Metastatic adenocarcinoma.
by Christian Grommes, Sarah S. Tang, Julia Wolfe, Thomas J
How I treat T-cell acute lymphoblastic leukemia in adults
Presentation transcript:

Central nervous system–restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation by Hojun Li, Leslie A. Benson, Lauren A. Henderson, Isaac H. Solomon, Alyssa L. Kennedy, Ariane Soldatos, Bibiana Bielekova, Jennifer Murphy, Kimberly J. Davies, Leslie E. Lehmann, Michelle A. Lee, Sanda Alexandrescu, Barbara A. Degar, Mark P. Gorman, and Christine N. Duncan BloodAdv Volume 3(4):503-507 February 26, 2019 ©2019 by American Society of Hematology

Baseline and posttreatment CNS-HLH patient characteristics. Baseline and posttreatment CNS-HLH patient characteristics. Baseline characteristics for all patients in this study, including age at onset of symptoms, nature of clinical symptoms, age at eventual diagnosis, familial HLH mutation, therapy received before CNS-HLH diagnosis, CSF assessment, and hematoxylin and eosin–stained brain biopsy histopathology (20× magnification). Black arrows indicate perivascular lymphocytic infiltrates. Also displayed are T1 MRI scans and NK-cell immunologic tests at diagnosis and after HCT. White arrows indicate contrast-enhancing MRI lesions. -, NK-cell testing not indicated for the patient’s specific mutation. HCT, hematopoietic cell transplantation; IVIG, intravenous immune globulin; MMF, mycophenolate mofetil; NK, natural killer; WBC, white blood cell. Hojun Li et al. Blood Adv 2019;3:503-507 ©2019 by American Society of Hematology